rostate canc
er) is a Phase I/IIa study for identification and treatment of PSMA-expressing metastatic castrate resistant prostate cancer (mCRPC), which will be conducted in the U.S. (NCT04868604)
[1]. It is a theranostic multi-centre, single arm, dose escalation study with a cohort expansion planned for up to 44 patients. The trial employs diagnostic Positron Emission Tomography imaging with
64Cu-SAR-bisPSMA for selection of patients suitable for therapy cycles with
67Cu-SAR-bis-PSMA.
Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of death worldwide
[2]. The American Cancer Society estimates in 2021 there will be 248,530 new cases of prostate cancer in the U.S. and around 34,130 deaths from the disease
Facts & Figures 2021 Reports Another Record-Breaking 1-Year Drop in Cancer Deaths
Facts & Figures 2021 Reports Another Record-Breaking 1-Year Drop in Cancer Deaths Written By:ACS Medical Content and News Staff January 12, 2021
The death rate from cancer in the United States has continued to decline. From 1991 to 2018, the cancer death rate has fallen 31%. This includes a 2.4% decline from 2017 to 2018 – a new record for the largest one-year drop in the cancer death rate. These are just some of the findings from the annual statistics reported by the American Cancer Society (ACS).
In Cancer Statistics, 2021 and its consumer-friendly companion,
Cancer Facts & Figures 2021, ACS researchers estimate that in the US in 2021, almost 1.9 million new cancer cases will be diagnosed. And more than 600,000 people will die from cancer.